MODEL SYSTEMS SHARED RESOURCE: BIOSAMPLE REPOSITORY FACILITY (BRF) PROJECT SUMMARY/ABSTRACT Fox Chase Cancer Center (FCCC) established biospecimen banking activities in 1987 to coordinate the ethical collection, storage, annotation and distribution of tissue and peripheral blood samples to support translational research. This centralized shared resource operates under the supervision of Denise Connolly, PhD (MT) and is advised by an inter-programmatic Facility Advisory Committee (FAC). To enhance BRF services, the Center invested $369,770 for a PE Vectra Multispectral Quantitative Imaging System and a MesoScale Discovery chemiluminescent ELISA platform. The Biosample Repository Facility (BRF) has three major functions: 1) to identify participants, obtain informed consent, collect tissue, blood and/or urine specimens and obtain information on personal and family histories of cancer, clinical intervention and lifestyle factors for use in research; 2) to process and store human biospecimens obtained through investigator-initiated studies; and 3) to provide tissue-related analysis services including custom tissue microarray (TMA) construction, standard immunoperoxidase and fluorescent immunohistochemical detection and analysis of biomarker expression. Working in collaboration with pathologists, medical oncologists, surgeons and other hospital personnel, specifically trained BRF staff obtains subject informed consent, collects samples and assembles comprehensive clinical, pathological and personal/demographic information about each donor and the corresponding samples. As part of this banking process, the BRF staff provides: 1) diagnostic pathology support; 2) a comprehensive informed consent process for the appropriate collection of tissue, blood and other biospecimens for research; 3) a specialized biospecimen bank devoted to the collection and distribution of de- identified specimens to support research; 4) custom TMA construction; 5) immunohistochemical staining; 6) computer assisted tissue analysis services; and 7) extensive supporting data from the clinical record and self- reported health history of each participant. All specimens collected by and housed in the BRF are linked to comprehensive clinical databases supported by the Population Studies Facility (PSF). The BRF currently houses over 16,500 fresh-frozen tissue samples, over 47,000 blood samples, and has access to >100,000 surgical pathology cases. The annual accruals for new tissue and blood specimens are approximately 1,500 and 3,000, respectively. In 2014, the BRF served 31 FCCC investigators (24 peer-review funded) across all five Research Programs. Ninety (90%) percent of the BRF's 2014 use (by primary service line) was by peer-review funded Cancer Center members. Future plans involve the Center's commitment to construct a dedicated freezer farm that will provide sample storage capacity for the next ten years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-53
Application #
9535096
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
53
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Malik, R; Luong, T; Cao, X et al. (2018) Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Matrix Biol :
Giri, Veda N; Obeid, Elias; Hegarty, Sarah E et al. (2018) Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling. Prostate 78:879-888
Anari, Fern; O'Neill, John; Choi, Woonyoung et al. (2018) Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol 1:54-60
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Nikonova, Anna S; Deneka, Alexander Y; Kiseleva, Anna A et al. (2018) Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD). FASEB J 32:2735-2746
Singh, Tanu; Lee, Eric H; Hartman, Tiffiney R et al. (2018) Opposing Action of Hedgehog and Insulin Signaling Balances Proliferation and Autophagy to Determine Follicle Stem Cell Lifespan. Dev Cell 46:720-734.e6
Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7

Showing the most recent 10 out of 1280 publications